Description

NLS Pharmaceutics AG is a biopharmaceutical firm dedicated to researching and creating treatments for intricate and uncommon conditions affecting the central nervous system. Its primary focus includes advancing medications for narcolepsy, idiopathic hypersomnia, and various other unusual sleep conditions, alongside neurodevelopmental challenges like attention deficit hyperactivity disorder (ADHD). Key experimental compounds in its pipeline are Quilience, designed to address excessive daytime sleepiness and cataplexy, and Nolazol, which targets ADHD. Established in 2015, the company maintains its headquarters in Zurich, Switzerland.